Inventiva S.A. Files 2024 Annual Report
Ticker: IVEVF · Form: 20-F · Filed: Apr 15, 2025 · CIK: 1756594
| Field | Detail |
|---|---|
| Company | Inventiva S.A. (IVEVF) |
| Form Type | 20-F |
| Filed Date | Apr 15, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: annual-report, pharmaceuticals, financials
TL;DR
Inventiva dropped its 2024 20-F, check financials and risks.
AI Summary
Inventiva S.A. filed its annual 20-F report for the fiscal year ending December 31, 2024. The filing details its financial position, business operations, and risk factors. Key financial data and corporate governance information are presented, reflecting the company's status as a pharmaceutical preparations company.
Why It Matters
This filing provides investors and stakeholders with a comprehensive overview of Inventiva's financial health and strategic direction for the past fiscal year, crucial for investment decisions.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Inventiva faces inherent risks related to drug development, regulatory approvals, and market competition, which are detailed in the 20-F.
Key Numbers
- 0.80 — Fiscal Year End (Indicates the end of the reporting period for the 2024 fiscal year.)
- 95662407 — Number of Shares (Likely represents outstanding shares or a related metric for the fiscal year.)
- 25000000 — Financial Metric (A significant financial figure, possibly related to debt or equity, for the fiscal year.)
Key Players & Entities
- Inventiva S.A. (company) — Filer of the 20-F report
- 2024-12-31 (date) — Fiscal year end
- 2025-04-15 (date) — Filing date
- David Nikodem (person) — Mentioned in relation to share warrant plans
FAQ
What were Inventiva's key financial results for the fiscal year ended December 31, 2024?
The 20-F filing for the period ending December 31, 2024, provides a comprehensive overview of Inventiva's financial performance, though specific line-item results like revenue or net income are not detailed in the provided header information.
What are the main business segments or products of Inventiva S.A. as described in the 20-F?
The filing identifies Inventiva S.A. under the Standard Industrial Classification code 2834, indicating its business is in Pharmaceutical Preparations.
Are there any significant legal or tax-related provisions mentioned for the fiscal year 2024?
The filing mentions provisions related to French Research Tax Credits for prior years (2013-2015 and 2017), indicating ongoing tax matters that may impact financial statements.
What is the nature of the 'Warrant Agreement with European Investment Bank' mentioned in the filing?
The filing references a 'Warrant Agreement with European Investment Bank' and 'LongTermFinancialDebtDerivatives' for the period ending December 31, 2024, suggesting financial instruments and potential debt obligations related to the EIB.
Who is David Nikodem and what is his relation to Inventiva S.A. based on this filing?
David Nikodem is mentioned in the context of 'Bsa20232ShareWarrantPlan' and 'Bsa20231ShareWarrantPlan' as of December 31, 2023, indicating involvement with the company's share warrant plans.
Filing Details
This Form 20-F (Form 20-F) was filed with the SEC on April 15, 2025 by David Nikodem regarding Inventiva S.A. (IVEVF).